Related Experiment Video

Updated: Aug 29, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

[Risks associated with hepatitis infection in patients with hepatitis C and opportunities for prophylaxis]

Sławomir Chlabicz1

  • 1Zakład Medycyny Rodzinnej i Pielegniarstwa Srodowiskowego Akademii Medycznej w Białymstoku. schlabicz@poczta.onet.pl

Przeglad Epidemiologiczny
|December 20, 2003
PubMed

Insights

Patients with chronic hepatitis C (HCV) are at risk for hepatitis A virus (HAV) infection, which can cause severe liver injury. Vaccination against HAV is recommended for unprotected HCV patients to prevent serious complications.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Vaccinology

Context:

  • Patients with chronic hepatitis C (HCV) are susceptible to hepatitis A virus (HAV) infection.
  • HCV patients with pre-existing liver disease face a higher risk of severe outcomes, including hepatitis fulminans and mortality, if infected with HAV.
  • In Poland, a significant portion of adults under 35 with HCV lack natural immunity to HAV.

Purpose:

  • To assess the risk of HAV infection in patients with chronic HCV.
  • To evaluate the safety and immunogenicity of inactivated HAV vaccines in HCV patients.
  • To determine the necessity of HAV vaccination in the HCV population.

Summary:

  • Chronic hepatitis C patients are at risk for HAV infection, with potentially higher incidence in anti-HCV positive drug users.
  • Hepatitis A infection is linked to increased hepatitis fulminans and mortality in individuals with pre-existing liver disease.
  • Inactivated HAV vaccine is safe and immunogenic in HCV patients, with vaccination recommended for unprotected individuals upon HCV diagnosis.

Impact:

  • Highlights the importance of HAV vaccination in preventing severe liver disease and mortality in HCV patients.
  • Provides evidence supporting the routine use of HAV vaccines in the management of chronic hepatitis C.
  • Informs public health strategies for hepatitis A and C prevention and control programs.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...